Pharvaris FY2026 EPS Estimate Reduced by Leerink Partnrs

Pharvaris (NASDAQ:PHVS) – Investment analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Pharvaris in a report released on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($2.87) per share for the year, down from their previous forecast of ($2.34). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

Pharvaris Price Performance

Shares of PHVS opened at $19.12 on Wednesday. Pharvaris has a 12-month low of $15.21 and a 12-month high of $33.00. The stock has a market capitalization of $999.78 million, a P/E ratio of -6.83 and a beta of -3.06. The firm’s 50 day moving average is $19.41 and its 200-day moving average is $19.35.

Institutional Trading of Pharvaris

Several institutional investors and hedge funds have recently bought and sold shares of PHVS. Public Employees Retirement System of Ohio purchased a new stake in shares of Pharvaris in the 3rd quarter valued at approximately $57,000. Barclays PLC acquired a new stake in shares of Pharvaris in the third quarter worth $106,000. HighVista Strategies LLC raised its position in Pharvaris by 35.9% during the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock valued at $422,000 after buying an additional 6,018 shares during the period. Jane Street Group LLC purchased a new stake in Pharvaris in the 3rd quarter worth about $526,000. Finally, Geode Capital Management LLC boosted its position in Pharvaris by 18.4% during the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after acquiring an additional 5,753 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.